Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia? (Q37975154)

26 August 2017

title

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia? (English)

1 reference

26 August 2017

0 references

5

Thorsten Zenz

1 reference

26 August 2017

Leopold Sellner

1

1 reference

26 August 2017

Sascha Dietrich

series ordinal

2

1 reference

26 August 2017

Peter Dreger

series ordinal

3

1 reference

26 August 2017

Hanno Glimm

series ordinal

4

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Current hematologic malignancy reports

26 August 2017

published in

1 reference

26 August 2017

volume

7

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

3-12

1 reference

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Localization of gene for human p53 tumour antigen to band 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Importance of genetics in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

21 January 2018

How I treat CLL up front

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

What is the best frontline therapy for patients with CLL and 17p deletion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of UnmutatedVHGene in Patients With Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0110-1

From pathogenesis to treatment of chronic lymphocytic leukaemia

21 January 2018

1 reference

12 December 2020

Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage

1 reference

12 December 2020

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

1 reference

12 December 2020

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Clinical staging of chronic lymphocytic leukemia

1 reference

12 December 2020

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

12 December 2020

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

1 reference

12 December 2020

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis

1 reference

12 December 2020

Allotransplantation for chronic lymphocytic leukemia

1 reference

12 December 2020

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

1 reference

12 December 2020

SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts

1 reference

12 December 2020

CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

10.1007/S11899-011-0110-1

Identifiers

DOI

1 reference

26 August 2017

1 reference